April 24- Zimmer Holdings Inc said on Thursday it would buy rival orthopedic products maker Biomet Inc for more than $13 billion, the latest deal in a wave of consolidations in the healthcare industry. The deal is expected to take Zimmer from the fourth-largest seller of orthopedics products to No. 2, behind Johnson& Johnson.» Read More
CNBC's David Faber has the latest details on a report Softbank is negotiating to buy 75 percent of Sprint Nextel.
Hedge fund heavy weights have been swapping investment ideas at the annual Value Investing Congress. Barry Rosenstein, Jana Partners founder, and CNBC's David Faber, discuss owning Agrium.
Energy-hungry China may not be done yet on the acquisition trail.
CNBC's Kayla Tausche has the details on the $3.7 billion deal.
CNBC's Kate Kelly has the details on a possible sale of Bank of America's non-U.S. wealth unit to Julius Baer for between $1 billion to $1.5 billion.
The memory of its failed 2005 bid for Unocal still fresh, China's state-controlled CNOOC Ltd. has put lessons learned into practice and "networked strongly" with regulators in Canada and the U.S., smoothing the way for its $15.1 billion all-cash deal to buy Canadian oil producer Nexen Inc.
CNBC's David Faber reports Glaxo will buy Human Genome for $14.24 per share, and TPG acquires generic drugmaker Par Pharma.
CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.
CNBC's Jon Fortt reports the latest details from RIM's annual shareholders meeting and Colin Gillis, BGC Partners analyst, discusses whether there are investment opportunities in the stock despite its downward spiral.
The "Squawk on the Street" news crew reports on what's going to drive the "buzz" and trading today, including the kick off to earnings season, and Wellpoint's acquisition of rival, Amerigroup.
Microsoft admits its acquisition of AQuantive is pretty much worthless now, with CNBC's Herb Greenberg.
A look at how uncertainty in global markets is impacting deal-making on Wall Street, with Ken Moelis, Moelis & Company founder & CEO.
This company has attracted more than two million users since it launched in March, making it one of the fastest growing photo-sharing platforms. Temo Chalasani, Cinemagram CEO & co-founder, discusses new trends in mobile apps and how he plans to outpace competitors.
Cisco's strategy chief, Ned Hooper is leaving the company, reports CNBC's Jon Fortt. The FMHR traders, weigh in.
Gigantic movie house, The Weinstein Company, has just secured $225 million in financing from UBS and Union Bank. CEO Harvey Weinstein discusses how his company will use the money to grow their business, the company's overseas success, the "Intouchables," and politics.
CNBC's David Faber breaks down the details on Walgreen's $6.7 billion acquisition of Alliance Boots, making it the largest buyer of pharmaceuticals in the world.
The "Squawk on the Street" news crew reports on where the rally is headed next; Microsoft's new tablet; JC Penney's executive shuffle; and Walgreen's deal to buy Alliance Boots for $6.7 billion in cash.
"We are going to be the largest buyer of prescription drugs," says Gregory Wasson, Walgreen CEO, with Stefano Pessina, Alliance Boots executive chairman, discussing Walgreen's $6.7 billion deal to buy a 45 percent stake in Alliance Boots with an option to buy the rest of the company.
The Marriott empire continues to grow with the acquisition of Gaylord Hotel brands. Arne Sorenson, Marriott International CEO, and Colin Reed, Gaylord Entertainment CEO, discuss the deal and the outlook on summer travel and the U.S. economy.
A look at the U.S. markets ahead of the open, with CNBC's Kelly Evans, including a look at G7 leaders meeting to discuss Europe's growing debt crisis and Starbucks' $100 million acquisition of a bread company.